Compare SCZM & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SCZM | TECX |
|---|---|---|
| Founded | N/A | 2019 |
| Country | Canada | United States |
| Employees | 455 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.2M | 618.9M |
| IPO Year | N/A | 2018 |
| Metric | SCZM | TECX |
|---|---|---|
| Price | $9.18 | $31.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $75.20 |
| AVG Volume (30 Days) | ★ 497.8K | 215.6K |
| Earning Date | 05-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $79.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.61 | $14.39 |
| 52 Week High | $17.65 | $39.53 |
| Indicator | SCZM | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 57.73 | 44.22 |
| Support Level | $8.64 | $27.30 |
| Resistance Level | $10.15 | $31.39 |
| Average True Range (ATR) | 0.54 | 2.57 |
| MACD | -0.06 | -0.54 |
| Stochastic Oscillator | 42.40 | 24.37 |
Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapa mine and processing plant, and Corporate and Other activities. Key revenue is generated from Zimapan.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.